Drugs /

pracinostat

Back to Drugs List
Associated Genetic Biomarkers

Overview

NCI Definition [1]:
An orally available, small-molecule histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Pracinostat inhibits HDACs, which may result in the accumulation of highly acetylated histones, followed by the induction of chromatin remodeling; the selective transcription of tumor suppressor genes; the tumor suppressor protein-mediated inhibition of tumor cell division; and, finally, the induction of tumor cell apoptosis. This agent may possess improved metabolic, pharmacokinetic and pharmacological properties compared to other HDAC inhibitors.

Clinical Trials

View Clinical Trials for pracinostat

Pracinostat has been investigated in 3 clinical trials, of which 1 is open and 2 are closed. Of the trials investigating pracinostat, 1 is phase 1 (1 open), 1 is phase 2 (0 open), and 1 is phase 3 (0 open).

Complex karyotype, Monosomy 7, and Normal karyotype are the most frequent biomarker inclusion criteria for pracinostat clinical trials.

Acute myeloid leukemia and myelodysplastic syndromes are the most common diseases being investigated in pracinostat clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Pracinostat
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Pracinostat
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating pracinostat and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
2-propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1h-benzimidazol-5-yl)-n-hydroxy-, (2e)-, kaempferol 3-o-beta-d-(6-e-p-coumaroylglucoside), hdac inhibitor sb939, hdac inhibitor sb939, pracinostat, sb939
Drug Categories [2]:
Histone deactylase/HDAC inhibitors
Drug Target(s) [2]:
HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
NCIT ID [1]:
C71708

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.